MIMEDX GROUP, INC.

(MDXG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MIMEDX GROUP, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

01/10/2022 | 08:08am EDT

Item 2.02 Results of Operation and Financial Condition

On January 10, 2022, MiMedx Group, Inc. (the "Company") issued a press release and presentation described further in Item 7.01 of this Current Report on Form 8-K (this "Current Report") providing certain unaudited preliminary financial results for the full year ended December 31, 2021.

Item 7.01 Regulation FD

Beginning on Monday, January 10, 2022, Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer, are expected to meet with investors and, on January 12, 2022, present at the 40th Annual J.P. Morgan Healthcare Conference on behalf of the Company, beginning at 5:15 p.m. Eastern Time. A copy of the presentation they will use is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The live webcast may be accessed on the Events page of the Investors section of the Company's website or by clicking here.

In addition, the Company also issued a press release on January 10, 2022, announcing its expectations as to certain financial and other results for the year ending December 31, 2022, which are also set forth in the presentation. A copy of the press release is furnished as Exhibit 99.2 to this Current Report and is incorporated herein by reference.

The information in this Current Report, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.
Exhibit No.              Description of Exhibit
99.1                       Slide Presentation dated January 10, 2022
99.2                       Press release dated January 10, 2022
                         The cover page from this Current Report on Form 8-K, formatted in Inline
104                      XBRL.

© Edgar Online, source Glimpses

All news about MIMEDX GROUP, INC.
05/26Institutional Shareholder Services Supports MiMedx Group Inc Nominees
CI
05/26Leading Independent Proxy Advisory Firm ISS Recommends That MIMEDX Shareholders Vote 'F..
AQ
05/25Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote &l..
AQ
05/24TRANSCRIPT : MiMedx Group, Inc. Presents at H.C. Wainwright Global Investment Conference 2..
CI
05/24MIMEDX GROUP, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23MiMedx Group, Inc. - Leading Independent Proxy Advisory Firm Glass Lewis Recommends Tha..
AQ
05/20MiMedx Says Glass Lewis Recommends in Favor of Director Nominees, Say-on-Pay Proposal
MT
05/20Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders..
AQ
05/20Glass Lewis & Co Supports MiMedx Group Inc Nominees and Proposals
CI
05/18MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation
AQ
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2022 273 M - -
Net income 2022 -30,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -13,7x
Yield 2022 -
Capitalization 431 M 431 M -
Capi. / Sales 2022 1,58x
Capi. / Sales 2023 1,38x
Nbr of Employees 811
Free-Float 97,9%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MDXG | US6024961012 | MarketScreener
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,83 $
Average target price 14,17 $
Spread / Average Target 270%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Scott M. Turner Vice President-Procurement
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-36.59%431
GILEAD SCIENCES, INC.-10.76%81 280
REGENERON PHARMACEUTICALS, INC.9.70%74 647
VERTEX PHARMACEUTICALS24.65%70 008
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437